UK

AstraZeneca bets on diabetes

British pharmaceutical company AstraZeneca buys out venture partner Bristol-Myers Squibb from diabetes drug alliance, ticking two growth priorities – diabetes and growth in emerging markets. Lex's Joseph Cotterill and Vincent Boland discuss the developments.